MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

James W. Antoon, Elizabeth C. Martin, Rongye Lai, Virgilo A. Salvo, Yan Tang, Ashley M. Nitzchke, Steven Elliott, Seung Yoon Nam, Wei Xiong, Lyndsay V. Rhodes, Bridgette Collins-Burow, Odile David, Guandi Wang, Bin Shan, Barbara S. Beckman, Kenneth P. Nephew, Matthew E. Burow

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Endocrine resistance and metastatic progression are primary causes of treatment failure in breast cancer. While mitogen activated protein kinases (MAPKs) are known to promote ligand-independent cell growth, the role of the MEK5-ERK5 pathway in the progression of clinical breast carcinoma remains poorly understood. Here, we demonstrated increased ERK5 activation in 30 of 39 (76.9%) clinical tumor samples, as well as across breast cancer cell systems. Overexpression of MEK5 in MCF-7 cells promoted both hormone-dependent and hormone-independent tumorigenesis in vitro and in vivo and conferred endocrine therapy resistance to previously sensitive breast cancer cells. Expression of MEK5 suppressed estrogen receptor (ER)α, but not ER-β protein levels, and abrogated downstream estrogen response element (ERE) transcriptional activity and ER-mediated gene transcription. Global gene expression changes associated with upregulation of MEK5 included increased activation of ER-α independent growth signaling pathways and promotion of epithelial-to-mesenchymal transition (EMT) markers. Taken together, our findings show that the MEK5-ERK5 pathway mediates progression to an ER(-), mesenchymal and endocrine therapy resistant phenotype. Given the need for new clinical therapeutic targets, our results demonstrate the therapeutic potential of targeting the MEK5-ERK5 pathway in breast cancer.

Original languageEnglish (US)
Article numbere69291
JournalPLoS ONE
Volume8
Issue number8
DOIs
StatePublished - Aug 9 2013

Fingerprint

Estrogen Receptors
breast neoplasms
carcinogenesis
Carcinogenesis
hormones
Hormones
Breast Neoplasms
therapeutics
Chemical activation
Cells
Cell growth
Response Elements
Transcription
Mitogen-Activated Protein Kinases
Gene expression
Epithelial-Mesenchymal Transition
response elements
MCF-7 Cells
Tumors
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Antoon, J. W., Martin, E. C., Lai, R., Salvo, V. A., Tang, Y., Nitzchke, A. M., ... Burow, M. E. (2013). MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis. PLoS ONE, 8(8), [e69291]. https://doi.org/10.1371/journal.pone.0069291

MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis. / Antoon, James W.; Martin, Elizabeth C.; Lai, Rongye; Salvo, Virgilo A.; Tang, Yan; Nitzchke, Ashley M.; Elliott, Steven; Nam, Seung Yoon; Xiong, Wei; Rhodes, Lyndsay V.; Collins-Burow, Bridgette; David, Odile; Wang, Guandi; Shan, Bin; Beckman, Barbara S.; Nephew, Kenneth P.; Burow, Matthew E.

In: PLoS ONE, Vol. 8, No. 8, e69291, 09.08.2013.

Research output: Contribution to journalArticle

Antoon, JW, Martin, EC, Lai, R, Salvo, VA, Tang, Y, Nitzchke, AM, Elliott, S, Nam, SY, Xiong, W, Rhodes, LV, Collins-Burow, B, David, O, Wang, G, Shan, B, Beckman, BS, Nephew, KP & Burow, ME 2013, 'MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis', PLoS ONE, vol. 8, no. 8, e69291. https://doi.org/10.1371/journal.pone.0069291
Antoon, James W. ; Martin, Elizabeth C. ; Lai, Rongye ; Salvo, Virgilo A. ; Tang, Yan ; Nitzchke, Ashley M. ; Elliott, Steven ; Nam, Seung Yoon ; Xiong, Wei ; Rhodes, Lyndsay V. ; Collins-Burow, Bridgette ; David, Odile ; Wang, Guandi ; Shan, Bin ; Beckman, Barbara S. ; Nephew, Kenneth P. ; Burow, Matthew E. / MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis. In: PLoS ONE. 2013 ; Vol. 8, No. 8.
@article{23ed55592b56479d86d2dd4da8fd8b5a,
title = "MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis",
abstract = "Endocrine resistance and metastatic progression are primary causes of treatment failure in breast cancer. While mitogen activated protein kinases (MAPKs) are known to promote ligand-independent cell growth, the role of the MEK5-ERK5 pathway in the progression of clinical breast carcinoma remains poorly understood. Here, we demonstrated increased ERK5 activation in 30 of 39 (76.9{\%}) clinical tumor samples, as well as across breast cancer cell systems. Overexpression of MEK5 in MCF-7 cells promoted both hormone-dependent and hormone-independent tumorigenesis in vitro and in vivo and conferred endocrine therapy resistance to previously sensitive breast cancer cells. Expression of MEK5 suppressed estrogen receptor (ER)α, but not ER-β protein levels, and abrogated downstream estrogen response element (ERE) transcriptional activity and ER-mediated gene transcription. Global gene expression changes associated with upregulation of MEK5 included increased activation of ER-α independent growth signaling pathways and promotion of epithelial-to-mesenchymal transition (EMT) markers. Taken together, our findings show that the MEK5-ERK5 pathway mediates progression to an ER(-), mesenchymal and endocrine therapy resistant phenotype. Given the need for new clinical therapeutic targets, our results demonstrate the therapeutic potential of targeting the MEK5-ERK5 pathway in breast cancer.",
author = "Antoon, {James W.} and Martin, {Elizabeth C.} and Rongye Lai and Salvo, {Virgilo A.} and Yan Tang and Nitzchke, {Ashley M.} and Steven Elliott and Nam, {Seung Yoon} and Wei Xiong and Rhodes, {Lyndsay V.} and Bridgette Collins-Burow and Odile David and Guandi Wang and Bin Shan and Beckman, {Barbara S.} and Nephew, {Kenneth P.} and Burow, {Matthew E.}",
year = "2013",
month = "8",
day = "9",
doi = "10.1371/journal.pone.0069291",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

AU - Antoon, James W.

AU - Martin, Elizabeth C.

AU - Lai, Rongye

AU - Salvo, Virgilo A.

AU - Tang, Yan

AU - Nitzchke, Ashley M.

AU - Elliott, Steven

AU - Nam, Seung Yoon

AU - Xiong, Wei

AU - Rhodes, Lyndsay V.

AU - Collins-Burow, Bridgette

AU - David, Odile

AU - Wang, Guandi

AU - Shan, Bin

AU - Beckman, Barbara S.

AU - Nephew, Kenneth P.

AU - Burow, Matthew E.

PY - 2013/8/9

Y1 - 2013/8/9

N2 - Endocrine resistance and metastatic progression are primary causes of treatment failure in breast cancer. While mitogen activated protein kinases (MAPKs) are known to promote ligand-independent cell growth, the role of the MEK5-ERK5 pathway in the progression of clinical breast carcinoma remains poorly understood. Here, we demonstrated increased ERK5 activation in 30 of 39 (76.9%) clinical tumor samples, as well as across breast cancer cell systems. Overexpression of MEK5 in MCF-7 cells promoted both hormone-dependent and hormone-independent tumorigenesis in vitro and in vivo and conferred endocrine therapy resistance to previously sensitive breast cancer cells. Expression of MEK5 suppressed estrogen receptor (ER)α, but not ER-β protein levels, and abrogated downstream estrogen response element (ERE) transcriptional activity and ER-mediated gene transcription. Global gene expression changes associated with upregulation of MEK5 included increased activation of ER-α independent growth signaling pathways and promotion of epithelial-to-mesenchymal transition (EMT) markers. Taken together, our findings show that the MEK5-ERK5 pathway mediates progression to an ER(-), mesenchymal and endocrine therapy resistant phenotype. Given the need for new clinical therapeutic targets, our results demonstrate the therapeutic potential of targeting the MEK5-ERK5 pathway in breast cancer.

AB - Endocrine resistance and metastatic progression are primary causes of treatment failure in breast cancer. While mitogen activated protein kinases (MAPKs) are known to promote ligand-independent cell growth, the role of the MEK5-ERK5 pathway in the progression of clinical breast carcinoma remains poorly understood. Here, we demonstrated increased ERK5 activation in 30 of 39 (76.9%) clinical tumor samples, as well as across breast cancer cell systems. Overexpression of MEK5 in MCF-7 cells promoted both hormone-dependent and hormone-independent tumorigenesis in vitro and in vivo and conferred endocrine therapy resistance to previously sensitive breast cancer cells. Expression of MEK5 suppressed estrogen receptor (ER)α, but not ER-β protein levels, and abrogated downstream estrogen response element (ERE) transcriptional activity and ER-mediated gene transcription. Global gene expression changes associated with upregulation of MEK5 included increased activation of ER-α independent growth signaling pathways and promotion of epithelial-to-mesenchymal transition (EMT) markers. Taken together, our findings show that the MEK5-ERK5 pathway mediates progression to an ER(-), mesenchymal and endocrine therapy resistant phenotype. Given the need for new clinical therapeutic targets, our results demonstrate the therapeutic potential of targeting the MEK5-ERK5 pathway in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84881250378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881250378&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0069291

DO - 10.1371/journal.pone.0069291

M3 - Article

C2 - 23950888

AN - SCOPUS:84881250378

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e69291

ER -